Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 715,224,192
  • Shares Outstanding, K 949,316
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • EBIT $ 13,467 M
  • EBITDA $ 14,994 M
  • 60-Month Beta 0.43
  • Price/Sales 20.30
  • Price/Cash Flow 95.68
  • Price/Book 48.37

Options Overview Details

View History
  • Implied Volatility 36.24% ( -2.39%)
  • Historical Volatility 35.20%
  • IV Percentile 79%
  • IV Rank 42.25%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.51
  • Today's Volume 43,726
  • Volume Avg (30-Day) 68,284
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 366,665
  • Open Int (30-Day) 321,392

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.48
  • Number of Estimates 8
  • High Estimate 5.59
  • Low Estimate 5.34
  • Prior Year 2.49
  • Growth Rate Est. (year over year) +120.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
711.40 +5.41%
on 11/18/24
911.12 -17.69%
on 10/22/24
-156.21 (-17.24%)
since 10/21/24
3-Month
711.40 +5.41%
on 11/18/24
972.53 -22.89%
on 08/22/24
-202.05 (-21.22%)
since 08/21/24
52-Week
561.65 +33.52%
on 12/15/23
972.53 -22.89%
on 08/22/24
+157.32 (+26.55%)
since 11/21/23

Most Recent Stories

More News
2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

AZN : 64.26 (+1.68%)
MRK : 99.86 (+2.48%)
LLY : 749.92 (-0.46%)
MRNA : 38.25 (+3.55%)
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.

LLY : 749.92 (-0.46%)
J&J Loses Around $24B in a Month: How to Play the Stock?

J&J JNJ stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and...

NVO : 102.63 (-2.51%)
JNJ : 155.50 (+1.56%)
LLY : 749.92 (-0.46%)
KVUE : 24.09 (+1.30%)
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley

For Immediate ReleaseChicago, IL – November 20, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

MS : 134.99 (+2.51%)
LLY : 749.92 (-0.46%)
PEP : 160.34 (+1.01%)
Is It Time to Sell Eli Lilly and Pfizer Stocks?

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) .

LLY : 749.92 (-0.46%)
PFE : 25.13 (+0.76%)
Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley

Tuesday, November 19, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and...

TT : 415.39 (+1.03%)
BABA : 85.58 (-1.37%)
MS : 134.99 (+2.51%)
LLY : 749.92 (-0.46%)
PEP : 160.34 (+1.01%)
DIS : 114.72 (+0.40%)
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyssâ„¢ (lebrikizumab)

/CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyssâ„¢...

LLY : 749.92 (-0.46%)
Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1...

NVO : 102.63 (-2.51%)
LLY : 749.92 (-0.46%)
ZLDPF : 99.3200 (-1.66%)
The Smartest Megacap Growth ETF to Buy With $500 Right Now

Growth stocks have soared this year as investors bet on an improving economic environment and technology players involved in the high-potential area of artificial intelligence (AI). This has helped the...

MGK : 335.86 (+0.13%)
MSFT : 412.87 (-0.63%)
NVDA : 146.67 (+0.53%)
AAPL : 228.52 (-0.21%)
TSLA : 339.64 (-0.70%)
LLY : 749.92 (-0.46%)
3 Growth Stocks You Can Buy Right Now Without Any Hesitation

Many investors have a type of acrophobia (the fear of heights). It's not that they're worried about standing at the top of a ladder. Instead, their concern is focused on putting money in stocks when the...

NVO : 102.63 (-2.51%)
LLY : 749.92 (-0.46%)
VRTX : 450.37 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 774.95
2nd Resistance Point 763.97
1st Resistance Point 756.95
Last Price 749.92
1st Support Level 738.95
2nd Support Level 727.97
3rd Support Level 720.95

See More

52-Week High 972.53
Fibonacci 61.8% 815.57
Fibonacci 50% 767.09
Last Price 749.92
Fibonacci 38.2% 718.61
52-Week Low 561.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar